Respicardia Announces Highmark Coverage for the remedē® System in Patients with Central Sleep Apnea
- Thursday, January 7, 2021, 7:12
- PR Newswire
- Add a comment
MINNETONKA, Minn., Jan. 7, 2021 /PRNewswire/ — Respicardia, Inc., the manufacturer of the only FDA-approved active implantable system for the treatment of central sleep apnea (CSA), announced today that Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the…
About the Author
admin has written 21793 stories on this site.